Analyst Price Targets — PACB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 8, 2025 11:46 am | Eve Burstein | Bernstein | $1.70 | $1.34 | TheFly | PacBio price target raised to $1.70 from $1.50 at Bernstein |
| June 25, 2025 9:12 am | Luke Sergott | Barclays | $1.50 | $1.22 | TheFly | PacBio price target lowered to $1.50 from $2 at Barclays |
| June 3, 2024 3:33 am | Tycho Peterson | Jefferies | $4.00 | $1.79 | StreetInsider | Jefferies Starts Pacific Biosciences of California (PACB) at Buy |
| May 13, 2024 12:08 pm | Tejas Savant | Morgan Stanley | $4.00 | $1.98 | TheFly | PacBio price target lowered to $4 from $10 at Morgan Stanley |
| May 13, 2024 6:50 am | David Westenberg | Piper Sandler | $2.00 | $1.77 | TheFly | PacBio price target lowered to $2 from $6.50 at Piper Sandler |
| May 10, 2024 5:25 am | Luke Sergott | Barclays | $2.00 | $1.72 | TheFly | PacBio price target lowered to $2 from $3 at Barclays |
| April 18, 2024 4:31 am | Matthew Sykes | Goldman Sachs | $2.50 | $1.40 | StreetInsider | Goldman Sachs Downgrades Pacific Biosciences of California (PACB) to Neutral |
| April 16, 2024 3:12 pm | Kyle Mikson | Canaccord Genuity | $3.50 | $1.40 | TheFly | PacBio price target lowered to $3.50 from $10 at Canaccord |
| November 16, 2022 9:16 am | — | Canaccord Genuity | $14.00 | $10.81 | Benzinga | Canaccord Genuity Maintains Buy on Pacific Biosciences, Raises Price Target to $14 |
| August 17, 2022 9:42 pm | David Westenberg | Piper Sandler | $7.50 | $7.61 | TheFly | Pacific Biosciences price target raised to $7.50 from $6 at Piper Sandler |
Latest News for PACB
Collaboration powers secure international data sharing through the HiFi Solves Global Consortium Collaboration powers secure international data sharing through the HiFi Solves Global Consortium
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) insider Christian Henry sold 331,793 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $1.58, for a total value of $524,232.94. Following the completion of the transaction, the insider owned 2,814,374 shares in
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026, at 2:30 PM ET in Boston, MA.
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PACB.
U.S. House Trading
No House trades found for PACB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.